Hirosaki University Hospital ( Site 1502)

Hirosaki, Aomori 036-8563

0 studies enrolling now · 1 studies all time

What they study most

Bladder Cancer

Studies at this site

• Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) — Completed